Lataa...
Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct(®))
BACKGROUND: Extended half-life (EHL) factor VIII (FVIII)-replacement therapies enable patients with haemophilia A to maintain higher activity levels with fewer injections. N8-GP (turoctocog alfa pegol; Esperoct(®)) is an EHL product derived from conjugation of polyethylene glycol (PEG) to a recombin...
Tallennettuna:
| Julkaisussa: | Drugs R D |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer International Publishing
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7221073/ https://ncbi.nlm.nih.gov/pubmed/32152818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-020-00297-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|